SPRO— AI Stock Forecast & Price Targets
Published 7/21/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live SPRO price forecast →
SPRO is an $83M micro-cap that just printed a fresh 52-week low at $1.41 despite two transformative deals (KKR $105M non-dilutive royalty + Innovent SP001/CD40L in-license up to $1.1B), a textbook signal that the tape is treating optionality as a liability rather than an asset. Q1'26 revenue collapsed 95% Q/Q to $258K, confirming there is no recurring business — this is a pure clinical/royalty option trading on execution, cash burn, and CD40L class safety. With RSI 23.6, price ~40% below all major SMAs, short float rising to 6.7%, and the 1-week model assigning 0% bullish probability, the risk/reward is asymmetric to the downside into the Aug 11 print.
1-4 weeks: HOLD/no new long. The Aug 11 earnings print (~21 days) is a binary catalyst — do NOT size a swing long into it. If already long, tolerate but consider trimming into any bounce toward $1.70-1.85 (SMA20 reclaim attempt). Invalidation for the bearish tape: a daily close back above $2.00 on volume. Downside stop-level: a decisive break below $1.35 opens $1.10-1.20. Do not chase oversold RSI here — this signal has failed repeatedly on this name.
1-6 months: The base case is that Utebzi royalty flow is real but slow to ramp and Innovent milestone outflows compress runway, forcing capital markets activity into a broken tape. The bull case requires (a) a clean Aug 11 print showing manageable burn, (b) tangible Utebzi commercial data from the GSK partnership, and (c) SP001 Phase 2 initiation timing. Expected return band: -25% to +45% from spot, skewed negative given the trend. What would change my mind: reclaim of $2.00 with rising volume, institutional ownership stepping above 18%, or an upside surprise on Utebzi royalty run-rate.
1-3 years: Terminal value hinges on SP001/IBI355 clearing the CD40L class-wide thromboembolism safety hurdle in Phase 2 and unlocking the Innovent milestone waterfall. If SP001 works, this is a multi-bagger from $1.44; if it fails on safety or efficacy, the Utebzi royalty stream is unlikely to support even current market cap after Innovent milestone outflows. The biggest structural risk is not clinical — it is that Innovent milestone payments arrive before Utebzi royalties scale, triggering dilution at a broken price. This is a binary optionality name, size accordingly.
Headline TTM optics (P/E 5.9, ROE 35%, profit margin 28%, EV/EBITDA 3.8) are milestone-accounting artifacts driven by the Q4'25 $39.7M revenue print ($31.4M op income) — the true operating picture is Q1'26 revenue of $258K (-94.95% Q/Q) with a -$7.5M operating loss, i.e., no recurring commercial business. The balance sheet is the one unambiguous positive: $56.1M cash vs $2.5M debt, current ratio 10.5, working capital $52.1M, and book value $0.91/sh — but Q1'26 operating cash flow of +$15.9M was milestone-driven and is not sustainable. The pending Innovent in-license (upfront + milestones per the 8-K) is a use of cash that could compress runway well before Utebzi/GSK royalties scale, and the $105M HealthCare Royalty facility is non-recourse against a not-yet-proven Utebzi ramp. Insider ownership 26% is a mild positive; institutional ownership 14.6% (declining, -1.55% instit trans) tells you no anchor holder is defending the tape.
The chart across all three timeframes is unambiguously broken. On the 1D, price has round-tripped from a $3.00 June high to $1.44 (-52%) with the forecast band sitting well above spot at ~$2.17, i.e., the model expects a bounce but has been wrong (bullish_prob 1wk = 0.00 and realized accuracy sub-baseline). Price is -29% below SMA20, -40.6% below SMA50, -40.1% below SMA200 — a full-bore downtrend with no reclaim attempts. RSI 23.6 has been persistently oversold for weeks; the calibration lesson here is that oversold has NOT been a bottom signal on this name. The prior $1.50 52-week low broke to $1.41 today (-8.86% on a session where the broader tape is only mildly risk-off), which is a structural break confirming distribution. Resistance stacks at $1.75 (recent shelf), $2.00 (psychological + prior consolidation), then $2.30-2.60 (SMA20/50 confluence). Support below $1.41 is air to the low-$1s.
The two headline catalysts are also the two most important signals: (1) the July 15 Innovent global-ex-China license for IBI355 (CD40L antibody) worth up to $1.1B in milestones, and (2) the July 14 $105M non-dilutive royalty financing from KKR-owned HealthCare Royalty monetizing future Utebzi cash flows. In a healthy tape, either would be a re-rating event; instead the stock is down ~34% on the week. The 8-K filed 7/14 explicitly flags large upfront and milestone payments to Innovent as a financial impact — the market appears to be pricing the Innovent outflows as a near-term cash drag that may outpace Utebzi royalty inflows, with SP001 Phase 2 readouts not expected until ~2027. Sell-side is quiet (Recom 3.0, target $4 looks stale), and social sentiment (100% bullish of the tagged messages) is a mild contrarian negative — retail is buying capitulation while insiders/institutions are not.
- SP001/IBI355 Phase 2 initiation and readout — unlocks up to $1.1B in Innovent milestones per the July 15 license (ex-Greater China rights)
- Utebzi (tebipenem HBr) US commercial ramp under GSK partnership — the cash-flow anchor for the $105M HealthCare Royalty/KKR facility
- Second wave of Utebzi milestones (US first sales, EU first sales, anniversary triggers) that could repay the KKR royalty and unlock incremental value
- SPR206 regional development under Everest Medicines in Greater China / South Korea / SEA — small but real optionality outside the SP001/Utebzi core
- Potential to repeat the non-dilutive royalty monetization playbook on future assets if Utebzi outperforms
- CD40L class-wide thromboembolism safety signal — a terminal risk to SP001 and the entire Innovent milestone waterfall
- Innovent upfront and milestone outflows (flagged in 7/14 8-K) may hit before Utebzi royalties scale, forcing dilution into a broken tape
- Q1'26 revenue of $258K (-95% Q/Q) confirms zero recurring business — the story is 100% milestone/royalty timing
- Technical trend is decisively broken: price at fresh 52-week low $1.41, -40% below all SMAs, RSI 23.6, and 1-week model bullish probability 0.00
- Short float rose from 4.3% → 6.7% in 45 days while institutional ownership sits at only 14.6% and declining — no anchor buyer to catch the falling knife
- Micro-cap liquidity (~$1.23M avg volume, $83M cap) amplifies drawdowns and complicates position exits
- Documented behavioral pattern on this name: positive catalysts have been consistently sold into rather than bought — sentiment/positioning is structurally hostile
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord